Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Illumina, Inc.    ILMN

Delayed Quote. Delayed  - 06/28 09:59:58 pm
135.01 USD   -0.35%
06/27 ILLUMINA : MolecularMD Enters Into a Collaboration Agreement With Il..
06/16 ILLUMINA : Announces Initial Customer Orders for the Global Screenin..
06/07 ILLUMINA : Announces Donald Danforth Plant Science Center to Receive..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 
The feature you requested does not exist. However, we suggest the following feature:

Illumina : MolecularMD Enters Into a Collaboration Agreement With Illumina for Drug-Diagnostic Co-Development With Biopharma Drug Programs

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/27/2016 | 06:01pm CEST

PORTLAND, OR and CAMBRIDGE, MA -- (Marketwired) -- 06/27/16 -- MolecularMD Corporation announced today that it has entered into an agreement with Illumina, Inc. (NASDAQ: ILMN) that establishes a framework for potential collaborations with respect to the development and commercialization of sequencing-based companion diagnostics in support of biopharma drug development program(s). The agreement dovetails MolecularMD's companion diagnostic development and FDA submission experience with Illumina's NGS technology.

"This agreement is designed to deliver the combined power of Illumina's NGS technologies with MolecularMD's ability to tailor a complete clinical development solution including regulatory planning, IDE validations and centralized testing and data management for global patient enrollment and disease monitoring," stated Dan Snyder, CEO of MolecularMD.

MolecularMD opened its advanced diagnostic laboratory in Cambridge, MA in 2012 with the objective of providing NGS solutions that support clinical trials of oncology drug programs. MolecularMD has since deployed NGS diagnostics over a broad range of drug targets and indications. The ability to support global trials with centralized testing laboratories while simultaneously obtaining necessary regulatory compliance can allow rapid deployment of Illumina based NGS solutions.

"Our goal is to enable our clients with the latest platforms and proven technologies that solve for the challenges that often arise during drug and diagnostic co-development," stated Snyder. "The ability to collaborate with Illumina on defined projects will greatly aid our clients to mitigate risks and to accelerate their clinical trial programs."

About MolecularMD

MolecularMD Corporation develops and commercializes specialty molecular diagnostics for oncology applications. Tests are designed to allow appropriate selection, monitoring and management of patients treated with molecularly-targeted cancer therapies. MolecularMD integrates gold-standard and innovative platform technologies with clinical assay design, validation and centralized testing to accelerate all phases of clinical development, including FDA approval and commercialization of in vitro companion diagnostic tests for novel anticancer agents.

   Media Inquiries:Tina BeaucheminMolecularMD(617) 575-2824 x613tbeauchemin@molecularmd.com

Source: MolecularMD

© Marketwire, source Press Releases

share with twitter share with LinkedIn share with facebook
share via e-mail
0
React to this article
Latest news on ILLUMINA, INC.
06/27 ILLUMINA : MolecularMD Enters Into a Collaboration Agreement With Illumina for D..
06/27 ILLUMINA : Combine Solicitation - AMD Illumina SA
06/24 ILLUMINA : Special Notice - Illumina Advantage Warranty and Service
06/24 SPECIAL NOTICE - NOTICE OF INTENT TO : Maintenance and Repair of Illumina Equipm..
06/23 ILLUMINA : Patent Issued for Selective Enrichment of Nucleic Acids (USPTO 936589..
06/23 ILLUMINA : Announces Initial Customer Orders for the Global Screening Array
06/20 ILLUMINA : Amendment to Combined Synopsis/Solicitation - Maintenance Agreement t..
06/17 ILLUMINA : Special Notice - Illumina Equipment Maintenance
06/16 ILLUMINA : Announces Donald Danforth Plant Science Center to Receive Agricultura..
06/16 ILLUMINA : Announces Initial Customer Orders for the Global Screening Array
Advertisement
News chart
Full-screen chart
Income Statement Evolution
More Financials